Review on molecular and therapeutic potential of thymoquinone in cancer

Nutrition and Cancer

Volumn 62, Issue 7, 2010, Pages 938-946

  Banerjee, Sanjeev ^a   Padhye, Subhash ^a   Azmi, Asfar ^a   Wang, Zhiwei ^a   Philip, Philip A ^a   Kucuk, Omer ^b   Sarkar, Fazlul H ^a   Mohammad, Ramzi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; MERCURIC CHLORIDE; OXALIPLATIN; THYMOQUINONE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROTECTION; CHEMOSENSITIZATION; COLON CANCER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EHRLICH ASCITES TUMOR; ENDOTHELIUM CELL; FIBROSARCOMA; HUMAN; IN VIVO STUDY; LIVER TOXICITY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PROSTATE CANCER; PROTEIN TARGETING; RENAL PROTECTION; REVIEW; STOMACH CANCER; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BENZOQUINONES; CELL CYCLE; CELL PROLIFERATION; HUMANS; NEOPLASMS; NF-KAPPA B;

NIGELLA SATIVA;

EID: 77958014176     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.509832     Document Type: Review

References (62)

1. Padhye S, Banerjee S, Ahmad A, Mohammad R, and Sarkar FH: From here to eternity-the secret of pharaohs: therapeutic potential of black cumin seeds and beyond. Cancer Ther 6, 495-510, 2008.
2. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, et al.: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69, 5575-5583, 2009.
3. Rooney S and Ryan MF: Effects of alpha-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines. Anticancer Res 25, 2199-2204, 2005.
4. Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, and Tithof PK: In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol 22, 107-113, 2003.
5. Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, et al.: Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol 25, 857-866, 2004.
6. Roepke M, Diestel A, Bajbouj K, Walluscheek D, Schonfeld P, et al.: Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther 6, 160-169, 2007.
7. Wilson-Simpson F, Vance S, and Benghuzzi H: Physiological responses of ES-2 ovarian cell line following administration of epigallocatechin-3-gallate (EGCG), thymoquinone (TQ), and selenium (SE). Biomed Sci Instrum 43, 378-383, 2007.
8. El-Mahdy MA, Zhu Q, Wang QE, Wani G, and Wani AA: Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer 117, 409-417, 2005.
9. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwari S, et al.: Androgen receptor and E2F-1 targeted thymoquinone therapy for hormonerefractory prostate cancer. Cancer Res 67, 7782-7788, 2007.
10. Chehl N, Chipitsyna G, Gong Q, Yeo CJ, and Arafat HA: Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) 11, 373-381, 2009.
11. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, et al.: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 7, 1789-1796, 2008.
12. Sethi G, Ahn KS, and Aggarwal BB: Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 6, 1059-1070, 2008.
13. Nohl H, Gille L, and Kozlov AV: Prooxidant functions of coenzyme Q. Subcell Biochem 30, 509-526, 1998.
14. Gali-Muhtasib H, Kuester D, Mawrin C, et al.: Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res 68, 5609-5618, 2008.
15. Balkwill F and Coussens LM: Cancer: an inflammatory link. Nature 431, 405-406, 2004.
16. Mansour MA, Nagi MN, El-Khatib AS, and Al-Bekairi AM: Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. Cell Biochem Funct 20, 143-151, 2002.
17. Hamdy NM and Taha RA: Effects of Nigella sativa oil and thymoquinone on oxidative stress and neuropathy in streptozotocin-induced diabetic rats. Pharmacology 84, 127-134, 2009.
18. Badary OA, Nagi MN, al-Shabanah OA, al-Sawaf HA, al-Sohaibani MO, et al.: Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol 75, 1356-1361, 1997.
19. Badary OA: Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol 67, 135-142, 1999.
20. Fouda AM, Daba MH, Dahab GM, and Sharaf El-Din OA: Thymoquinone ameliorates renal oxidative damage and proliferative response induced by mercuric chloride in rats. Basic Clin Pharmacol Toxicol 103, 109-118, 2008.
21. Al-Johar D, Shinwari N, Arif J, Al-Sanea N, Jabbar AA, et al.: Role of Nigella sativa and a number of its antioxidant constituents towards azoxymethane-induced genotoxic effects and colon cancer in rats. Phytother Res 22, 1311-1323, 2008.
22. Mansour MA: Protective effects of thymoquinone and desferrioxamine against hepatotoxicity of carbon tetrachloride in mice. Life Sci 66, 2583-2591, 2000.
23. Mansour MA, Ginawi OT, El-Hadiyah T, El-Khatib AS, Al-Shabanah OA, et al.: Effects of volatile oil constituents of Nigella sativa on carbon tetrachloride-induced hepatotoxicity in mice: evidence for antioxidant effects of thymoquinone. Res Commun Mol Pathol Pharmacol 110, 239-251, 2001.
24. Nagi MN, Alam K, Badary OA, al-Shabanah OA, al-Sawaf HA, et al.: Thymoquinone protects against carbon tetrachloride hepatotoxicity in mice via an antioxidant mechanism. Biochem Mol Biol Int 47, 153-159, 1999.
25. Khattab MM and Nagi MN: Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. Phytother Res 21, 410-414, 2007.
26. Nagi MN and Almakki HA: Thymoquinone supplementation induces quinone reductase and glutathione transferase in mice liver: possible role in protection against chemical carcinogenesis and toxicity. Phytother Res 23, 1295-1298, 2009.
27. Badary OA and Gamal El-Din AM: Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. Cancer Detect Prev 25, 362-368, 2001.
28. Mousavi SH, Tayarani-Najaran Z, Asghari M, and Sadeghnia HR: protective effect of Nigella sativa extract and thymoquinone on serum/glucose deprivation-induced PC12 cells death. Cell Mol Neurobiol.
29. Buchanan FG and DuBois RN: Connecting COX-2 and Wnt in cancer. Cancer Cell 9, 6-8, 2006.
30. Wang D and DuBois RN: Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett 267, 197-203, 2008.
31. El Mezayen R, El Gazzar M, Nicolls MR, Marecki JC, Dreskin SC, et al.: Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol Lett 106, 72-81, 2006. (Pubitemid 44093055)
32. Mansour M and Tornhamre S: Inhibition of 5-lipoxygenase and leukotriene C4 synthase in human blood cells by thymoquinone. J Enzyme Inhib Med Chem 19, 431-436, 2004.
33. El-Dakhakhny M, Madi NJ, Lembert N, and Ammon HP: Nigella sativa oil, nigellone and derived thymoquinone inhibit synthesisof5-lipoxygenase products in polymorphonuclear leukocytes from rats. J Ethnopharmacol 81, 161-164, 2002.
34. El Gazzar MA: Thymoquinone suppressses in vitro production of IL-5 and IL-13 by mast cells in response to lipopolysaccharide stimulation. Inflamm Res 56, 345-351, 2007.
35. El-Gouhary I, Mohamed A, Suleiman S, and Benghuzzi H: Comparison of the amelioration effects of two enzyme inducers on the inflammatory process of experimental allergic encephalitis (EAE) using immunohistochemical technique. Biomed Sci Instrum 41, 376-381, 2005.
36. Mohamed A, Afridi DM, Garani O, and Tucci M: Thymoquinone inhibits the activation of NF-kappaB in the brain and spinal cord of experimental autoimmune encephalomyelitis. Biomed Sci Instrum 41, 388-393, 2005.
37. Sayed AA and Morcos M: Thymoquinone decreases AGE-induced NF-kappaB activation in proximal tubular epithelial cells. Phytother Res 21, 898-899, 2007.
38. Ivankovic S, Stojkovic R, Jukic M, Milos M, and Jurin M: The antitumor activity of thymoquinone and thymohydroquinone in vitro and in vivo. Exp Oncol 28, 220-224, 2006.
39. Womack K, Anderson M, Tucci M, Hamadain E, and Benghuzzi H: Evaluation of bioflavonoids as potential chemotherapeutic agents. Biomed Sci Instrum 42, 464-469, 2006.
40. Tan M, Norwood A, May M, Tucci M, and Benghuzzi H: Effects of (-) epigallocatechin gallate and thymoquinone on proliferation of a PANC-1 cell line in culture. Biomed Sci Instrum 42, 363-371, 2006.
41. Richards LR, Jones P, Hughes J, Benghuzzi H, and Tucci M: The physiological effect of conventional treatment with epigallocatechin-3-gallate, thymoquinone, and tannic acid on the LNCaP cell line. Biomed Sci Instrum 42, 357-362, 2006.
42. Martin TM, Benghuzzi H, and Tucci M: The effect of conventional and sustained delivery of thymoquinone and levodopa on SH-SY5Y human neuroblastoma cells. Biomed Sci Instrum 42, 332-337, 2006.
43. McDermott C, O'Donoghue MH, and Heffron JJ: n-Hexane toxicity in Jurkat T-cells is mediated by reactive oxygen species. Arch Toxicol 82, 165-171, 2008.
44. Gali-Muhtasib H, Ocker M, Kuester D, Krueger S, El-Hajj Z, et al.: Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J Cell Mol Med 12, 330-342, 2008.
45. Yamasaki L: Role of the RB tumor suppressor in cancer. Cancer Treat Res 115, 209-239, 2003.
46. Alhosin M, Abusnina A, Achour M, Sharif T, Muller C, et al.: Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol 79, 1251-1260, Biochemical pharmacology.
47. Torres MP, Ponnusamy MP, Chakraborty S, Smith LM, Das S, et al.: Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther.
48. Cecarini V, Quassinti L, Di Blasio A, Bonfili L, Bramucci M, et al.: Effects of thymoquinone on isolated and cellular proteasomes. FEBS J 277, 2128-2141.
49. Al-Naqeep G, Ismail M, and Allaudin Z: Regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme a reductase gene expression by thymoquinone-rich fraction and thymoquinone in HepG2 cells. J Nutrigenetics Nutrigenomics 2, 163-172, 2009.
50. Gali-Muhtasib HU, Abou Kheir WG, Kheir LA, Darwiche N, and Crooks PA: Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs 15, 389-399, 2004.
51. Badary OA, Al-Shabanah OA, Nagi MN, Al-Rikabi AC, and Elmazar MM: Inhibition of benzo (a) pyrene-induced forestomach carcinogenesis in mice by thymoquinone. Eur J Cancer Prev 8, 435-440, 1999.
52. al-Shabanah OA, Badary OA, Nagi MN, al-Gharably NM, al-Rikabi AC, et al.: Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J Exp Clin Cancer Res 17, 193-198, 1998.
53. Badary OA, Abdel-Naim AB, Abdel-Wahab MH, and Hamada FM: The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats. Toxicology 143, 219-226, 2000.
54. Gali-Muhtasib H, Roessner A, and Schneider-Stock R: Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 38, 1249-1253, 2006.
55. Hochhauser D: Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. Anticancer Drugs 8, 903-910, 1997.
56. Barron J, Benghuzzi H, and Tucci M: Effects of thymoquinone and selenium on the proliferation of mg 63 cells in tissue culture. Biomed Sci Instrum 44, 434-440, 2008.
57. Worthen DR, Ghosheh OA, and Crooks PA: The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res 18, 1527-1532, 1998.
58. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, et al.: Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65, 9064-9072, 2005.
59. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, et al.: In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 120, 906-917, 2007. (Pubitemid 46175414)
60. Effenberger K, Breyer S, and Schobert R: Terpene conjugates of the Nigella sativa seed-oil constituent thymoquinone with enhanced efficacy in cancer cells. Chem Biodivers 7, 129-139.
61. Banerjee S, Azmi AS, Padhye S, Singh MW, Baruah JB, et al.: Structureactivity studies on therapeutic potential of thymoquinone analogs in pancreatic cancer. Pharm Res.
62. Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, et al.: Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced antiproliferative, anti-inflammatory, and chemosensitization potential. Biochem Pharm 79, 1640-1647.